The Debiopharm Group today announced the establishment of a Debiopharm oncology chair at (EPFL), focusing on Signal Transduction in Oncogenesis. Funded through a CHF 2.5 million endowment, the Chair will support the research work of Assistant Professor Dr Joerg Huelsken, of the EPFL Faculty of Life Sciences, which focuses on the role of the WNT signalling pathway in tumorigenesis and stem cell maintenance.